Corticosteroids in Duchenne muscular dystrophy: major variations in practice.
Muscle Nerve
; 48(1): 27-31, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23483575
ABSTRACT
INTRODUCTION:
In 2004, a Cochrane Review and AAN practice parameter concluded that prednisone 0.75 mg/kg/day is of short-term efficacy in Duchenne muscular dystrophy (DMD). Subsequent efforts to standardize care for DMD indicated wide variation in corticosteroid use.METHODS:
We surveyed physicians who follow patients with DMD, including (1) clinics in the TREAT-NMD (Translational Research in Europe-Assessment and Treatment of Neuromuscular Diseases) network (predominantly Europe) and (2) U.S. MDA clinic directors. We also documented the co-administered corticosteroids in a trial of a putative treatment (ataluren) for DMD.RESULTS:
Of 105 Treat-NMD clinicians, corticosteroids were not used in 10 clinics, and 29 different regimens were used--the most frequent 0.75 mg/kg/day prednisone (61 centers); 10 days on/10 days off (36 centers); 0.9 mg/kg/day deflazacort (32 centers); and 5 mg/kg/day on weekends (10 centers). Similar diversity was identified in MDA clinics and in the ataluren trial.CONCLUSIONS:
Variability in corticosteroid use suggests uncertainty about risks/benefits of corticosteroid regimens for DMD.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Médicos
/
Coleta de Dados
/
Corticosteroides
/
Distrofia Muscular de Duchenne
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limite:
Humans
País/Região como assunto:
America do norte
/
Europa
Idioma:
En
Revista:
Muscle Nerve
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos